Table 1. Characteristics of study participants from the MoBa and Senior cohort, by menopausal status.
Postmenopausal women (n = 7725) | Perimenopausal women (n = 7148) | Premenopausal, nonmenstruating (n = 7052) | |
---|---|---|---|
Cohort | |||
MoBa*, n (%) | 5710 (73.9) | 7148 (100) | 7052 (100) |
Senior cohort†, n (%) | 2015 (26.1) | 0 | 0 |
Age groups, n (%) | |||
<35 | 0 | 0 | 13 (0.2) |
35–39 | 4 (0.1) | 13 (0.2) | 335 (4.8) |
40–44 | 43 (0.6) | 150 (2.1) | 1953 (27.7) |
45–49 | 380 (4.9) | 1593 (22.3) | 3417 (48.5) |
50–54 | 2299 (29.8) | 4380 (61.3) | 1254 (17.8) |
55–59 | 2550 (33.0) | 998 (14.0) | 70 (1.0) |
60–64 | 434 (5.6) | 14 (0.2) | 10 (0.1) |
65–69 | 653 (8.5) | 0 | 0 |
70–74 | 740 (9.6) | 0 | 0 |
75–79 | 528 (6.8) | 0 | 0 |
≥ 80 | 94 (1.2) | 0 | 0 |
Age, median | 56 | 52 | 45 |
Fill in date‡, median (min, max) | 2 Sep (20 Aug, 19 Oct) | 1 Sep (20 Aug, 16 Sep) | 1 Sep (20 Aug, 16 Sep) |
COVID-19 vaccination status | |||
Dose 1, n (%) | 7574 (98.0) | 7016 (98.2) | 6941 (98.4) |
Date dose 1‡, median (IQR) | 12 May (2 Apr–17 Jun) | 16 Jun (5 May–24 Jun) | 21 Jun (30 Apr–1 Jul) |
Interval in days (dose 1–dose 2), median (IQR) | 42 (42–57) | 49 (42–61) | 44 (41–57) |
Vaxzevria (AstraZenaca), n (%) | 449 (5.9) | 554 (7.9) | 653 (9.4) |
Comirnaty (Pfizer-BioNTech), n (%) | 5860 (77.4) | 5538 (78.9) | 5482 (79.0) |
Spikevax (Moderna), n (%) | 1263 (16.7) | 923 (13.2) | 806 (11.6) |
Other, n (%) | 2 (<0.1) | 1 (<0.1) | 0 |
Dose 2, n (%) | 7337 (95.0) | 6669 (93.3) | 6450 (91.5) |
Date dose 2‡, median (IQR) | 18 Jun (19 May–12 Aug) | 8 Aug (16 Jun–18 Aug) | 9 Aug (9 Jun–19 Aug) |
Interval in days (dose 2–fill in date), median (IQR) | 75 (21–125) | 26 (14–78) | 25 (13–84) |
Vaxzevria (AstraZeneca), n (%) | 0 | 2 (<0.1) | 0 |
Comirnaty (Pfizer-BioNTech), n (%) | 5847 (76.2) | 5016 (75.2) | 4883 (75.7) |
Spikevax (Moderna), n (%) | 1750 (23.9) | 1650 (24.7) | 1567 (24.3) |
Other, n (%) | 0 | 1 (<0.1) | 0 |
Hormone/contraception use, n (%) | |||
Yes§ | 2044 (26.5) | 4089 (57.2) | 6030 (85.5) |
No | 5681 (73.5) | 3059 (42.8) | 1022 (14.5) |
Any gynecological condition, n (%) | |||
Yes║ | 1247 (16.1) | 1379 (19.3) | 1020 (14.5) |
No¶ | 6193 (80.2) | 5441 (76.1) | 5843 (82.9) |
Do not know, n (%) | 285 (3.7) | 328 (4.6) | 189 (2.7) |
*MoBa participants.
†Senior cohort participants.
‡All dates are in 2021.
§Women who reported use of combination pill, progestin-only pill, IUD (hormonal), IUD (copper), contraceptive implant, other contraception, HRT, and other hormone treatment (details are presented in table S1).
║Women who reported to have had myomas/adenomyosis, endometriosis, polycystic ovary syndrome, cervical cancer, endometrial cancer, or “other gynecological condition” (details are presented in table S1).
¶Women answered “No” to all abovementioned items.